Graft-versus-host disease risk factors: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Graft-versus-host disease}} | {{Graft-versus-host disease}} | ||
{{CMG}} | {{CMG}} {{shyam}} | ||
==Overview== | ==Overview== | ||
| Line 7: | Line 7: | ||
==Risk Factors== | ==Risk Factors== | ||
Risk factors for GvHD include: | |||
*High degree of HLA disparity between host and donor cells<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | |||
*Use of unrelated donors as the stem cell source<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | |||
*Total body irradiation as the conditioning regimen prior to transplant<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | |||
Protective risk factors include: | |||
*High degree of HLA concordance between the host and donor | |||
*Use of umbilical cord blood as the donor source (given decreased number of donor T cells) | |||
==References== | ==References== | ||
Revision as of 17:54, 14 June 2017
|
Graft-versus-host disease |
|
Differentiating Graft-versus-host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Graft-versus-host disease risk factors On the Web |
|
American Roentgen Ray Society Images of Graft-versus-host disease risk factors |
|
Risk calculators and risk factors for Graft-versus-host disease risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
Risk Factors
Risk factors for GvHD include:
- High degree of HLA disparity between host and donor cells[1]
- Use of unrelated donors as the stem cell source[1]
- Total body irradiation as the conditioning regimen prior to transplant[1]
Protective risk factors include:
- High degree of HLA concordance between the host and donor
- Use of umbilical cord blood as the donor source (given decreased number of donor T cells)
References
- ↑ 1.0 1.1 1.2 Rezvani AR, Storb RF (2012). "Prevention of graft-vs.-host disease". Expert Opin Pharmacother. 13 (12): 1737–50. doi:10.1517/14656566.2012.703652. PMC 3509175. PMID 22770714.